ACON on Nasdaq
Aclarion, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with SERA PROGNOSTICS, INC., YD Bio Ltd or Renalytix plc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
9.0%Gross margin3
-9312.5%Operating margin3
-9551.9%Net margin3
65.6%Revenue growth, 20253
-56.4%Return on equity3
-$7.2MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue6¢$68.9K
- Research and development94¢$1.0M
Out of $75.7K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $75.7K | $45.7K |
| Cost of revenue | $68.9K | $84.7K |
| Gross profit (loss) | $6.8K | -$38.9K |
| Sales and marketing | $1.9M | $976.6K |
| Research and development | $1.0M | $888.8K |
| General and administrative | $4.1M | $3.6M |
| Total operating expenses | $7.1M | $5.5M |
| Loss from operations | -$7.1M | -$5.5M |
| Interest expense | $0 | -$535.5K |
| Loss on exchange of debt | $0 | -$1.1M |
| Gain on extinguishment of debt | $73.3K | $6.1K |
| Changes in fair value of warrant and derivative liabilities | $11.8K | $335.0K |
| Penalties and settlements | -$672.6K | -$212.5K |
| Interest income | $411.1K | $318 |
| Other, net | -$4.8K | -$49 |
| Total other expense | -$181.2K | -$1.5M |
| Loss before income taxes | -$7.2M | -$7.0M |
| Income tax provision | $0 | $0 |
| Net loss | -$7.2M | -$7.0M |
| Dividends on preferred stock | -$6.7K | -$59.7K |
| Net loss allocable to common stockholders | -$7.2M | -$7.1M |
| Net loss per share allocable to common stockholders, basic | -$13.61 | -$7,478.90 |
| Net loss per share allocable to common stockholders, diluted | -$13.61 | -$7,478.90 |
| Weighted average shares of common stock outstanding, basic | 532.0K shares | 943 shares |
| Weighted average shares of common stock outstanding, diluted | 532.0K shares | 943 shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $12.0M | $453.7K | |
| Restricted cash | $25.0K | $10.0K | |
| Accounts receivable, net | $29.7K | $18.3K | |
| Prepaid expense | $41.3K | $4.2K | |
| Other current assets | $0 | $158.7K | |
| Total current assets | $12.4M | $824.3K | |
| Property and equipment, net | $24.2K | $5.5K | |
| Intangible assets, net | $1.3M | $1.3M | |
| Total non-current assets | $1.3M | $1.3M | |
| Total assets | $13.7M | $2.1M | |
| Accounts payable | $333.0K | $6.0K | |
| Accrued and other liabilities | $10.0K | $529.2K | |
| Warrant liability | $63 | $11.9K | |
| Liability to issue equity | $0 | $80.8K | |
| Total current liabilities | $837.3K | $1.2M | |
| Total liabilities | $837.3K | $1.2M | |
| Additional paid-in capital | $71.3M | $52.2M | |
| Accumulated deficit | -$58.5M | -$51.3M | |
| Total stockholders equity | $12.8M | $970.1K | -$728.0K |
| Total liabilities and stockholders equity | $13.7M | $2.1M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 854.4K shares | 1.4K shares | |
| Common stock, shares outstanding | 854.4K shares | 1.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$7.2M | -$7.0M |
| Depreciation and amortization | $227.4K | $193.1K |
| Share-based compensation | $105.4K | $287.5K |
| Amendment of warrants | $48.1K | $0 |
| Non-cash settlements | $58.3K | $0 |
| Loss on exchange of debt | $0 | $1.1M |
| Loss on extinguishment of debt | $0 | $111.9K |
| Amortization of deferred issuance costs | $0 | $471.4K |
| Change in fair value related to warrants and derivative | -$11.8K | -$335.0K |
| Non-cash interest related to bridge funding | $0 | $58.0K |
| Non-cash expenses related to equity line agreement | $0 | $425.4K |
| Accounts receivable | -$11.4K | $7.3K |
| Prepaids and other current assets | $16.1K | -$287.7K |
| Accounts payable | -$198.6K | -$156.4K |
| Accrued and other liabilities | -$164.0K | -$127.4K |
| Net cash used in operating activities | -$7.2M | -$5.3M |
| Intangible assets Patents | -$182.4K | -$316.8K |
| Fixed assets | -$21.5K | -$5.1K |
| Net cash used in investing activities | -$203.9K | -$321.9K |
| Public offering of common stock and warrants | $14.6M | $3.0M |
| Registered direct offerings of common stock | $5.7M | $0 |
| Proceeds from direct offering of prefunded warrants | $2.0M | $0 |
| Proceeds from sale of preferred stock | $0 | $1.0M |
| Proceeds from sale of common stock and warrants, ATM | $0 | $288.3K |
| Common stock cash issuance costs | -$2.4M | -$788.1K |
| Exercise of Series C warrants | $336.4K | $0 |
| Redemption of Series B Preferred stock | -$1.2M | $0 |
| Proceeds from common stock and warrant RegA+ offering | $0 | $529.3K |
| Proceeds from equity line | $0 | $1.8M |
| Repayment of promissory notes | $0 | -$301.0K |
| Equity line cash issuance costs | $0 | -$367.9K |
| Preferred stock cash issuance costs | $0 | -$90.0K |
| Net cash provided by financing activities | $18.9M | $5.0M |
| Net increase (decrease) in cash and cash equivalents | $11.6M | -$567.4K |
| Cash paid for interest | $0 | $13.1K |
| Cash paid for income taxes | $1.7K | $0 |
| Capitalization of Series B preferred stock dividends | $5.4K | $0 |
| Capitalization of Series C preferred stock dividends | $1.3K | $0 |
| Conversion of Series C preferred stock to common stock | $548.5K | $0 |
| Cashless exercise of B warrants to common stock | $9.5M | $0 |
| Dividends accrued on preferred shares | $0 | $59.7K |
| Exchange of indebtedness for common shares | $0 | $1.8M |
| Exchange of indebtedness for preferred shares | $0 | $930.1K |
| Conversion of preferred stock to common stock | $0 | $130.0K |
| Issuance of common shares related to restricted stock units | $0 | $216.6K |
| Issuance of commitment shares related to bridge funding | $0 | $33.3K |
Former names
- Nocimed, Inc.Mar 3, 2015 to Oct 26, 20212
Recent filings
- Aug 19, 20264
- Aug 18, 20264
- Aug 17, 20264
- Aug 17, 20264
- Aug 17, 20264
- Aug 17, 20264
- Aug 6, 202610-Q FORM 10-Q FOR JUN 2026
- Jul 9, 2026S-8 REGISTRATION STATEMENT
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
- Jun 12, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAclarion, Inc. filings on SEC EDGAR
- 2SEC EDGARAclarion, Inc. filings on SEC EDGAR
- 3SEC EDGARAclarion, Inc. 10-K for fiscal 2025
- 4SEC EDGARAclarion, Inc. 10-K for fiscal 2021
- 5SEC EDGARAclarion, Inc. 10-K for fiscal 2022
- 6SEC EDGARAclarion, Inc. 10-K for fiscal 2023
- 7SEC EDGARAclarion, Inc. 10-Q for fiscal 2026
- 8SEC EDGARAclarion, Inc. 10-Q for fiscal 2026
- 9SEC EDGARAclarion, Inc. 10-K for fiscal 2021